biostudies-literatureBlaney SM5 U01NCRRNCRR NIH HHSNCI NIH HHS627-32https://www.ebi.ac.uk/biostudies/studies/S-EPMC3573253biostudies-literatureUnknown60(4)<h4>Purpose</h4>We performed a phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan (IT), administered daily 5×, to determine whether, the maximum tolerated dose of IT topotecan was also the pharmacokinetic optimal dose.<h4>Patients and methods</h4>Patients received topotecan administered through an intraventricular access device (0.1 or 0.2 mg/dose), daily × 5 every other week 2× (Induction); every 3 weeks × 2 (Consolidation); then every 4 weeks for up to 11 courses (Maintenance). Ventricular CSF pharmacokinetic studies were performed on day 1, week 1 of induction, and in a subset of patients after a single intralumbar topotecan dose on day 1, week 3.<h4>Results</h4>Nineteen patients were enrolled. All were evaluable for toxicity and 18 were assessable for pharmacokiPediatric blood & cancerA phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study.PMC3573253U01 CA081457CA81457M01 RR00188M01 RR000188Boyett JBlaney SMKun LOnar-Thomas AStewart CBerg SLSu JTagen MScorsone KGoldman SKieran MWGururangan SfalseA phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study.<h4>Purpose</h4>We performed a phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan (IT), administered daily 5×, to determine whether, the maximum tolerated dose of IT topotecan was also the pharmacokinetic optimal dose.<h4>Patients and methods</h4>Patients received topotecan administered through an intraventricular access device (0.1 or 0.2 mg/dose), daily × 5 every other week 2× (Induction); every 3 weeks × 2 (Consolidation); then every 4 weeks for up to 11 courses (Maintenance). Ventricular CSF pharmacokinetic studies were performed on day 1, week 1 of induction, and in a subset of patients after a single intralumbar topotecan dose on day 1, week 3.<h4>Results</h4>Nineteen patients were enrolled. All were evaluable for toxicity and 18 were assessable for pharmacoki2013-01-01T00:00:00Z2013 Apr2025-04-26T08:55:24.193Z2019-03-27T01:04:52ZS-EPMC35732532300203910.1002/pbc.24309